MARKET

APLS

APLS

Apellis Pharmace
NASDAQ

Real-time Quotes | Nasdaq Last Sale

64.29
+1.96
+3.14%
After Hours: 62.05 -2.24 -3.48% 18:19 08/09 EDT
OPEN
63.45
PREV CLOSE
62.33
HIGH
65.50
LOW
61.28
VOLUME
1.13M
TURNOVER
0
52 WEEK HIGH
67.74
52 WEEK LOW
27.50
MARKET CAP
6.85B
P/E (TTM)
-8.0133
1D
5D
1M
3M
1Y
5Y
Where Apellis Pharmaceuticals Stands With Analysts
  Within the last quarter, Apellis Pharmaceuticals (NASDAQ:APLS) has observed the following analyst ratings:
Benzinga · 15h ago
Apellis (APLS) Q2 Earnings and Sales Miss Estimates, Stock Down
Apellis' (APLS) missed earnings and sales estimates in the second quarter of 2022. Consequently, the stock declines.
Zacks · 18h ago
--Credit Suisse Raises Apellis Pharmaceuticals' Price Target to $52 from $49, Updates Model with Q2 Actuals; Keeps Neutral Rating
--Credit Suisse Raises Apellis Pharmaceuticals' Price Target to $52 from $49, Updates Model with Q2 Actuals; Keeps Neutral Rating
MT Newswires · 1d ago
--Raymond James Adjusts Price Target on Apellis Pharmaceuticals to $113 From $102, Reiterates Strong Buy Rating
--Raymond James Adjusts Price Target on Apellis Pharmaceuticals to $113 From $102, Reiterates Strong Buy Rating
MT Newswires · 1d ago
Apellis Pharmaceuticals: Q2 Earnings Insights
  Apellis Pharmaceuticals (NASDAQ:APLS) reported its Q2 earnings results on Monday, August 8, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Benzinga · 1d ago
Apellis Pharmaceuticals, Inc. (APLS) Reports Q2 Loss, Misses Revenue Estimates
Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -2.10% and 4.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 1d ago
Apellis Pharmaceuticals Q2 EPS $(1.46) Misses $(1.36) Estimate, Sales $16.32M Miss $16.94M Estimate
Apellis Pharmaceuticals (NASDAQ:APLS) reported quarterly losses of $(1.46) per share which missed the analyst consensus estimate of $(1.36) by 7.35 percent. This is a 46.32 percent increase over losses of $(2.72) per
Benzinga · 1d ago
Apellis Pharmaceuticals GAAP EPS of -$1.46 misses by $0.09, revenue of $16.32M misses by $0.63M
Apellis Pharmaceuticals press release (<span class="ticker-hover-wra...
Seekingalpha · 1d ago
More
No Data
Learn about the latest financial forecast of APLS. Analyze the recent business situations of Apellis Pharmace through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 18 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

38.89%Strong Buy
44.44%Buy
11.11%Hold
5.56%Under-perform
0.00%Sell
Analyst Price Target
The average APLS stock price target is 74.88 with a high estimate of 113.00 and a low estimate of 40.00.
High113.00
Average74.88
Low40.00
Current 64.29
EPS
Actual
Estimate
-1.82-1.37-0.91-0.46
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 262
Institutional Holdings: 106.12M
% Owned: 99.62%
Shares Outstanding: 106.52M
TypeInstitutionsShares
Increased
72
12.28M
New
52
4.83M
Decreased
63
5.44M
Sold Out
22
1.74M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.23%
Pharmaceuticals & Medical Research
-0.22%
Key Executives
Non-Executive Chairman/Independent Director
Gerald Chan
President/Chief Executive Officer/Co-Founder/Director
Cedric Francois
Co-Founder/Chief Scientific Officer
Pascal Deschatelets
Chief Financial Officer/Treasurer
Timothy Sullivan
Chief Operating Officer/Chief Technology Officer
Nur Nicholson
Chief Accounting Officer/Vice President/Controller
James Chopas
General Counsel
David Watson
Other
Jeff Eisele
Other
Federico Grossi
Other
Lukas Scheibler
Other
Adam Townsend
Independent Director
A. Sinclair Dunlop
Independent Director
Paul Fonteyne
Independent Director
Alec Machiels
Independent Director
Stephanie O'Brien
No Data
No Data
About APLS
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that is focused on developing therapeutic compounds to treat disease through the inhibition of the complement system. The Company is developing pegcetacoplan with Sobi for systemic administration in several indications, including paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy, immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, cold agglutinin disease, and hematopoietic stem cell transplantation thrombotic microangiopathy. The Company's advanced clinical programs targeting component 3 with Phase III clinical trials of its lead product candidate, pegcetacoplan, in multiple indications. Pegcetacoplan is a conjugate of a compstatin analogue, formulated both for ophthalmological administration by injections directly into the eye, and systemic administration by subcutaneous injection, which is an injection into the tissue under the skin.

Webull offers kinds of Apellis Pharmaceuticals Inc stock information, including NASDAQ:APLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, APLS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading APLS stock methods without spending real money on the virtual paper trading platform.